Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > Irritable Bowel Syndrome - Pipeline Review, H2 2016 Irritable Bowel Syndrome - Pipeline Review, H2 2016 Publication ID: GMD1116025 Publication November 16, 2016 Date: Pages: 140 Publisher: Global Markets Direct Countries: Global [1] $2,000.00 Publication License Type * SINGLE USER LICENSE (PDF), $2,000.00 SITE LICENSE (PDF), $4,000.00 GLOBAL LICENSE (PDF), $6,000.00 Please choose the suitable license type from above. More details are at given under tab "Report License Types" below.
Add to cart Diseases [2] Pharma & Healthcare [3] Description: Irritable Bowel Syndrome - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Irritable Bowel Syndrome Pipeline Review, H2 2016, provides an overview of the Irritable Bowel Syndrome (Gastrointestinal) pipeline landscape. Inflammatory Bowel Diseases (IBD) is a broad term that describes conditions with chronic or recurring immune response and inflammation of the gastrointestinal tract. Signs and symptoms include abdominal cramps and pain, diarrhea that may be bloody, weight loss, loss of appetite and fever. The predisposing factors include age, family history, smoking and some pain killers. Treatment includes corticosteroids, immune suppressors, antibiotics and pain relievers. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Irritable Bowel Syndrome Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Irritable Bowel Syndrome (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Irritable Bowel Syndrome (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Irritable Bowel Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 10, 6, 9 and 1 respectively.irritable Bowel Syndrome. Irritable Bowel Syndrome (Gastrointestinal) pipeline guide helps in identifying and tracking
emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Irritable Bowel Syndrome (Gastrointestinal). - The pipeline guide reviews pipeline therapeutics for Irritable Bowel Syndrome (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Irritable Bowel Syndrome (Gastrointestinal) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Irritable Bowel Syndrome (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Irritable Bowel Syndrome (Gastrointestinal) Reasons to buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Irritable Bowel Syndrome (Gastrointestinal). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it s most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Irritable Bowel Syndrome (Gastrointestinal) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline. Table Of Contents: Table of Contents Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Irritable Bowel Syndrome Overview 10 Therapeutics Development 11 Pipeline Products for Irritable Bowel Syndrome - Overview 11 Irritable Bowel Syndrome - Therapeutics under Development by Companies 12 Irritable Bowel Syndrome - Pipeline Products Glance 14 Late Stage Products 14 Clinical Stage Products 15 Early Stage Products 16 Irritable Bowel Syndrome - Products under Development by Companies 17 Irritable Bowel Syndrome - Companies Involved in Therapeutics Development 19 4D Pharma Plc 19 A. Menarini Industrie Farmaceutiche Riunite Srl 20 Alfa Wassermann S.p.A 21 Ardelyx, Inc. 22 Astellas Pharma Inc. 23 CJ HealthCare Corp. 24 Dong-A Socio Holdings Co. Ltd. 25 Enterome Bioscience SA 26 GlaxoSmithKline Plc 27 Innovative Med Concepts, LLC 28 Ironwood Pharmaceuticals, Inc. 29 Kissei Pharmaceutical Co., Ltd. 30 Lexicon Pharmaceuticals, Inc. 31
Napo Pharmaceuticals Inc 32 Ono Pharmaceutical Co., Ltd. 33 Pfizer Inc. 34 RaQualia Pharma Inc. 35 RedHill Biopharma Ltd. 36 SK Biopharmaceuticals Co., Ltd. 37 Sumitomo Dainippon Pharma Co Ltd 38 Synergy Pharmaceuticals, Inc. 39 Synthetic Biologics, Inc. 40 Vitality Biopharma Inc 41 Irritable Bowel Syndrome - Therapeutics Assessment 42 Assessment by Monotherapy Products 42 Assessment by Combination Products 43 Assessment by Target 44 Assessment by Mechanism of Action 46 Assessment by Route of Administration 49 Assessment by Molecule Type 51 Drug Profiles 53 (celecoxib + famciclovir) - Drug Profile 53 Product Description 53 Mechanism Of Action 53 R&D Progress 53 ASP-1017 - Drug Profile 54 Product Description 54 Mechanism Of Action 54 R&D Progress 54 ASP-7147 - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 bedoradrine sulfate - Drug Profile 56 Product Description 56 Mechanism Of Action 56 R&D Progress 56 Blautix - Drug Profile 59 Product Description 59 Mechanism Of Action 59 R&D Progress 59 CJ-14199 - Drug Profile 60 Product Description 60
Mechanism Of Action 60 R&D Progress 60 crofelemer DR - Drug Profile 61 Product Description 61 Mechanism Of Action 61 R&D Progress 61 CSTI-300 - Drug Profile 64 Product Description 64 Mechanism Of Action 64 R&D Progress 64 DA-6886 - Drug Profile 65 Product Description 65 Mechanism Of Action 65 R&D Progress 65 DSP-6952 - Drug Profile 66 Product Description 66 Mechanism Of Action 66 R&D Progress 66 EB-420 - Drug Profile 67 Product Description 67 Mechanism Of Action 67 R&D Progress 67 GSK-3179106 - Drug Profile 68 Product Description 68 Mechanism Of Action 68 R&D Progress 68 ibodutant - Drug Profile 69 Product Description 69 Mechanism Of Action 69 R&D Progress 69 linaclotide - Drug Profile 70 Product Description 70 Mechanism Of Action 70 R&D Progress 70 lovastatin - Drug Profile 77 Product Description 77 Mechanism Of Action 77 R&D Progress 77 LT-4006 - Drug Profile 81 Product Description 81
Mechanism Of Action 81 R&D Progress 81 LX-1033 - Drug Profile 82 Product Description 82 Mechanism Of Action 82 R&D Progress 82 ondansetron hydrochloride CR - Drug Profile 84 Product Description 84 Mechanism Of Action 84 R&D Progress 84 ONO-2952 - Drug Profile 89 Product Description 89 Mechanism Of Action 89 R&D Progress 89 ORP-101 - Drug Profile 90 Product Description 90 Mechanism Of Action 90 R&D Progress 90 PBF-677 - Drug Profile 91 Product Description 91 Mechanism Of Action 91 R&D Progress 91 plecanatide - Drug Profile 92 Product Description 92 Mechanism Of Action 92 R&D Progress 92 pregabalin - Drug Profile 100 Product Description 100 Mechanism Of Action 100 R&D Progress 100 relenopride hydrochloride - Drug Profile 104 Product Description 104 Mechanism Of Action 104 R&D Progress 104 rifaximin - Drug Profile 105 Product Description 105 Mechanism Of Action 105 R&D Progress 105 RQ-00202730 - Drug Profile 109 Product Description 109
Mechanism Of Action 109 R&D Progress 109 RQ-00310941 - Drug Profile 110 Product Description 110 Mechanism Of Action 110 R&D Progress 110 Small Molecules to Inhibit 5-HT2B and 5-HT7 Receptors for IBS and Migraine - Drug Profile 111 Product Description 111 Mechanism Of Action 111 R&D Progress 111 solabegron hydrochloride - Drug Profile 112 Product Description 112 Mechanism Of Action 112 R&D Progress 112 tenapanor hydrochloride - Drug Profile 114 Product Description 114 Mechanism Of Action 114 R&D Progress 114 VB-210 - Drug Profile 119 Product Description 119 Mechanism Of Action 119 R&D Progress 119 Irritable Bowel Syndrome - Dormant Projects 120 Irritable Bowel Syndrome - Discontinued Products 125 Irritable Bowel Syndrome - Product Development Milestones 126 Featured News & Press Releases 126 Nov 03, 2016: RedHill Biopharma Provides Update on Ongoing Phase III and Phase II studies with BEKINDA and Expected Timing of Top-Line Results 126 Oct 19, 2016: Ardelyx Announces the Presentation of Positive Global Endpoint Findings from Phase 2b Trial of Tenapanor in Patients with IBS-C at ACG Annual Meeting 127 Oct 17, 2016: Synergy Pharmaceuticals Presents Long-Term Data for Plecanatide in Chronic Idiopathic Constipation at the American College of Gastroenterology Annual Scientific Meeting 128 Sep 28, 2016: Synergy Pharmaceuticals Announces New Plecanatide Data Presentations at Upcoming Scientific Meeting and Provides Update on IBS-C Program 129 Aug 02, 2016: Synthetic Biologics Announces Completion of End of Phase 2 Meeting with FDA for SYN-010, Intended for the Treatment of Irritable Bowel Syndrome with Constipation 130 Jul 19, 2016: 4D Pharma Provides Phase I Clinical Trial Update 130 Jul 15, 2016: Synergy Pharmaceuticals Provides Update on Ongoing FDA Review of Plecanatide CIC NDA and IBS-C Clinical Development Program 131 Jun 20, 2016: RedHill Biopharma Announces First Patients Dosed in Phase II Study with BEKINDA for
IBS-D 132 May 24, 2016: Synergy Pharmaceuticals Presents New In Vitro Data Showing the ph-dependent Activity of Plecanatide Replicates That of Naturally Occurring GI Peptide Uroguanylin 133 May 23, 2016: Phase I trial Update On Blautix For The Treatment Of Irritable Bowel Syndrome : 4D pharma 133 May 23, 2016: Synthetic Biologics Announces Detailed Data from Two SYN-010 Phase 2 Clinical Trials for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C) 134 May 17, 2016: Ironwood Pharmaceuticals to Present Linaclotide Data at Digestive Disease Week 2016 135 May 17, 2016: Synthetic Biologics to Host Post-DDW 2016 Conference Call to Recap SYN-010 Phase 2 Clinical Trial Results for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C) 136 May 16, 2016: Synergy Pharmaceuticals to Present New Plecanatide Data at Digestive Disease Week 2016 136 May 11, 2016: Isaac J. Bright, MD, Joins Synthetic Biologics as Vice President, Corporate Development 137 Appendix 139 Methodology 139 Coverage 139 Secondary Research 139 Primary Research 139 Expert Panel Validation 139 Contact Us 139 Disclaimer 140 List of Tables Number of Products under Development for Irritable Bowel Syndrome, H2 2016 11 Number of Products under Development by Companies, H2 2016 12 Number of Products under Development by Companies, H2 2016 (Contd..1) 13 Comparative Analysis by Late Stage Development, H2 2016 14 Comparative Analysis by Clinical Stage Development, H2 2016 15 Comparative Analysis by Early Stage Development, H2 2016 16 Products under Development by Companies, H2 2016 17 Products under Development by Companies, H2 2016 (Contd..1) 18 Irritable Bowel Syndrome - Pipeline by 4D Pharma Plc, H2 2016 19 Irritable Bowel Syndrome - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H2 2016 20 Irritable Bowel Syndrome - Pipeline by Alfa Wassermann S.p.A, H2 2016 21 Irritable Bowel Syndrome - Pipeline by Ardelyx, Inc., H2 2016 22 Irritable Bowel Syndrome - Pipeline by Astellas Pharma Inc., H2 2016 23 Irritable Bowel Syndrome - Pipeline by CJ HealthCare Corp., H2 2016 24 Irritable Bowel Syndrome - Pipeline by Dong-A Socio Holdings Co. Ltd., H2 2016 25
Irritable Bowel Syndrome - Pipeline by Enterome Bioscience SA, H2 2016 26 Irritable Bowel Syndrome - Pipeline by GlaxoSmithKline Plc, H2 2016 27 Irritable Bowel Syndrome - Pipeline by Innovative Med Concepts, LLC, H2 2016 28 Irritable Bowel Syndrome - Pipeline by Ironwood Pharmaceuticals, Inc., H2 2016 29 Irritable Bowel Syndrome - Pipeline by Kissei Pharmaceutical Co., Ltd., H2 2016 30 Irritable Bowel Syndrome - Pipeline by Lexicon Pharmaceuticals, Inc., H2 2016 31 Irritable Bowel Syndrome - Pipeline by Napo Pharmaceuticals Inc, H2 2016 32 Irritable Bowel Syndrome - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016 33 Irritable Bowel Syndrome - Pipeline by Pfizer Inc., H2 2016 34 Irritable Bowel Syndrome - Pipeline by RaQualia Pharma Inc., H2 2016 35 Irritable Bowel Syndrome - Pipeline by RedHill Biopharma Ltd., H2 2016 36 Irritable Bowel Syndrome - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2016 37 Irritable Bowel Syndrome - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2016 38 Irritable Bowel Syndrome - Pipeline by Synergy Pharmaceuticals, Inc., H2 2016 39 Irritable Bowel Syndrome - Pipeline by Synthetic Biologics, Inc., H2 2016 40 Irritable Bowel Syndrome - Pipeline by Vitality Biopharma Inc, H2 2016 41 Assessment by Monotherapy Products, H2 2016 42 Assessment by Combination Products, H2 2016 43 Number of Products by Stage and Target, H2 2016 45 Number of Products by Stage and Mechanism of Action, H2 2016 47 Number of Products by Stage and Route of Administration, H2 2016 50 Number of Products by Stage and Molecule Type, H2 2016 52 Irritable Bowel Syndrome - Dormant Projects, H2 2016 120 Irritable Bowel Syndrome - Dormant Projects (Contd..1), H2 2016 121 Irritable Bowel Syndrome - Dormant Projects (Contd..2), H2 2016 122 Irritable Bowel Syndrome - Dormant Projects (Contd..3), H2 2016 123 Irritable Bowel Syndrome - Dormant Projects (Contd..4), H2 2016 124 Irritable Bowel Syndrome - Discontinued Products, H2 2016 125 List of Figures Number of Products under Development for Irritable Bowel Syndrome, H2 2016 11 Number of Products under Development by Companies, H2 2016 12 Comparative Analysis by Late Stage Development, H2 2016 14 Comparative Analysis by Clinical Stage Development, H2 2016 15 Comparative Analysis by Early Stage Products, H2 2016 16 Assessment by Monotherapy Products, H2 2016 42 Number of Products by Top 10 Targets, H2 2016 44 Number of Products by Stage and Top 10 Targets, H2 2016 44 Number of Products by Top 10 Mechanism of Actions, H2 2016 46 Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 46
Number of Products by Routes of Administration, H2 2016 49 Number of Products by Stage and Routes of Administration, H2 2016 49 Number of Products by Molecule Types, H2 2016 51 Number of Products by Stage and Molecule Types, H2 2016 51 Companies Mentioned: 4D Pharma Plc A. Menarini Industrie Farmaceutiche Riunite Srl Alfa Wassermann S.p.A Ardelyx, Inc. Astellas Pharma Inc. CJ HealthCare Corp. Dong-A Socio Holdings Co. Ltd. Enterome Bioscience SA GlaxoSmithKline Plc Innovative Med Concepts, LLC Ironwood Pharmaceuticals, Inc. Kissei Pharmaceutical Co., Ltd. Lexicon Pharmaceuticals, Inc. Napo Pharmaceuticals Inc Ono Pharmaceutical Co., Ltd. Pfizer Inc. RaQualia Pharma Inc. RedHill Biopharma Ltd. SK Biopharmaceuticals Co., Ltd. Sumitomo Dainippon Pharma Co Ltd Synergy Pharmaceuticals, Inc. Synthetic Biologics, Inc. Vitality Biopharma Inc License Types: Single User License (PDF) This license allows for use of a publication by one person. This person may print out a single copy of the publication. This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher. This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization. Customers who infringe these license terms are liable for a Global license fee. Site License (PDF)* This license allows for use of a publication by all users within one corporate location, e.g. a regional office. These users may print out a single copy of the publication. These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher. These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased. Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization. Customers who infringe these license terms are liable for a Global license fee. Global License (PDF)* This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company. Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization. These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher. *If Applicable. Source URL: https://www.marketresearchreports.com/global-markets-direct/irritable-bowel-syndrome-pipline-review-h2-2016 Links [1] https://www.marketresearchreports.com/countries/global [2] https://www.marketresearchreports.com/diseases [3] https://www.marketresearchreports.com/pharma-healthcare